NEW YORK (GenomeWeb News) – Myriad Genetics has chosen Topin & Associates to help with its marketing strategy for a molecular diagnostic test to determine proper dosing for cancer drug 5-fluorouracil.
Under the terms of the deal, Topin will create a marketing strategy around the test, called OnDose, and prepare material in order to aid Myriad's sales force in selling the test to oncologists.
OnDose, which was launched in 2009, measures the level of 5-fluorouracil from a patient's blood sample. Using that information, a physician can make better dosing decisions to improve efficacy and reduce toxicity.
5-fluorouracil is used primarily in colorectal cancer and pancreatic cancer.
Topin and its medical educational partner, Advanced Clinical Concepts, also will conduct meetings in which the OnDose technology will be discussed in greater detail and compared with other methods of determining 5-fluorouracil measurement, including the body surface area method, the current standard for determining dosing of the drug.
Financial and other terms of the deal were not disclosed.